DBV Technologies price target raised to $20 from $16 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on DBV Technologies (DBVT) to $20 from $16 and keeps a Buy rating on the shares following the Q3 report. The firm says that with the VITESSE Phase 3 data expected in Q4 and dual application filings planned in 2026 for children and toddlers, DBV is positioned to deliver the first broadly accessible epicutaneous immunotherapy. A positive VITESSE readout “could unlock both regulatory momentum and warrant-linked capital,” extending DBV’s cash runway into commercialization, the analyst tells investors in a research note.